Marksans Pharma

Unifi Capital, a Chennai-based asset management firm known for its value-driven investment philosophy, has exited its position in Marksans Pharma Ltd., a mid-cap pharmaceutical company. The move signals a broader rebalancing of the fund’s portfolio as it reassesses sectoral exposure and redeploys capital into new opportunities. While the sale may raise questions about Marksans Pharma’s near-term prospects, market watchers interpret the transaction as a routine investment rotation rather than a bearish outlook.

In a significant market move, OrbiMed, a US-based investment firm, sold a 2.27% stake in Marksans Pharma for Rs 257 crore through an open market transaction. The stake, amounting to over 1.02 crore shares, was sold at an average price of Rs 249.95 per share, reducing OrbiMed's holding in the pharmaceutical company to 8.61%. The transaction, valued at Rs 256.78 crore, saw notable buyers including Citigroup, Societe Generale, and several mutual funds. Following the sale, Marksans Pharma's share price rose by 5.62%, closing at Rs 264 on the NSE, signaling strong investor interest.